Inebilizumab for neuromyelitis optica spectrum disorder in Italy: a budget impact model

CONCLUSION: Inebilizumab reduces the INHS expenditure for NMOSD drugs. Future research should explore the cost-effectiveness of inebilizumab vs other NMOSD-targeting drugs in Italy.PMID:37795872 | DOI:10.1080/14737167.2023.2267176

Source: Expert Review of Pharmacoeconomics and Outcomes Research - October 5, 2023 Category: Health Management Authors: Carlo Lazzaro Nicola Amedeo Mazzanti Silvia Rossi Fabio Parazzini Source Type: research